Tivozanib fails in colorectal cancer; Aveo takes a dive
By Catherine Shaffer
Friday, December 13, 2013
The hits keep coming for Aveo Pharmaceuticals Inc., as its once-daily VEGF receptor tyrosine kinase inhibitor failed another indication, this time colorectal cancer (CRC).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.